BC001 Combined TAS-102 in a multicenter phase II clinical study in patients with metastatic colorectal cancer who have failed or not tolerated first-and second-line standard therapy
Ontology highlight
ABSTRACT: Interventions: Experimental group:BC001 combined with TAS-102 treatment
Primary outcome(s): BC001 Safety of combined TAS-102 in patients with metastatic colorectal cancer who failed or tolerated first-line and second-line standard treatment, including: adverse events, blood routine, blood chemistry and urine routine, physical examination, vital signs and electrocardiogram results.
Study Design: Single arm
DISEASE(S): Patients With Metastatic Colorectal Cancer Who Fail Or Do Not Tolerate First-line And Second-line Standard Therapy
PROVIDER: 86191 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA